Dow Can Thank Caterpillar and Goldman Sachs for Getting to 40K

The Dow Jones Industrial Average made history, but it's not because of big tech.

BarronsMay 16 22:45

Roche's New Weight-Loss Data Shows Lilly Isn't Unbeatable in Obesity -- Barrons.com

By Josh Nathan-Kazis Roche unveiled impressive early-stage results in a small trial of a weight-loss drug called CT-388 that could make the company a serious player in the obesity-drug market in the

Barron'sMay 16 22:08

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo FinanceMay 16 21:00

Early clinical trials of Roche (RHHBY.US) diet pills achieved positive results: average weight loss of 18.8% after 24 weeks

In December of last year, Roche acquired US private clinical-stage biotechnology company Carmot Therapeutics for $2.7 billion in cash. It was through this acquisition that Roche acquired CT-388, a clinical-stage asset to join the diet drug market dominated by Novo Nordisk (NVO.US) and LLY.US (LLY.US). Other pharmaceutical companies developing diet pills include Amgen (AMGN.US), Pfizer (PFE.US), and AstraZeneca (AZN.US).

Zhitong FinanceMay 16 20:56

Roche Obesity Therapy Leads to ~19% Weight Loss in Phase 1 Trial

Seeking AlphaMay 16 18:48

Amgen Options Spot-On: On May 15th, 149.31K Contracts Were Traded, With 209.27K Open Interest

On May 15th ET, $Amgen(AMGN.US)$ had active options trading, with a total trading volume of 149.31K options for the day, of which put options accounted for 4.34% of the total transactions, and call op

Futu NewsMay 16 04:30